Aclarion (ACON) Competitors $7.41 -0.28 (-3.64%) As of 06/12/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON vs. BRTX, MGRX, SSY, OTRK, BGLC, VSEE, DHAC, ATIP, NIVF, and BACKShould you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include BioRestorative Therapies (BRTX), Mangoceuticals (MGRX), SunLink Health Systems (SSY), Ontrak (OTRK), BioNexus Gene Lab (BGLC), Vsee Health (VSEE), Digital Health Acquisition (DHAC), ATI Physical Therapy (ATIP), NewGenIvf Group (NIVF), and IMAC (BACK). These companies are all part of the "healthcare" industry. Aclarion vs. Its Competitors BioRestorative Therapies Mangoceuticals SunLink Health Systems Ontrak BioNexus Gene Lab Vsee Health Digital Health Acquisition ATI Physical Therapy NewGenIvf Group IMAC BioRestorative Therapies (NASDAQ:BRTX) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Which has more volatility and risk, BRTX or ACON? BioRestorative Therapies has a beta of 76.75, meaning that its stock price is 7,575% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Which has higher earnings and valuation, BRTX or ACON? Aclarion has lower revenue, but higher earnings than BioRestorative Therapies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioRestorative Therapies$391K38.39-$14.41M-$1.47-1.36Aclarion$54.60K78.98-$4.91MN/AN/A Do analysts rate BRTX or ACON? BioRestorative Therapies presently has a consensus price target of $18.00, suggesting a potential upside of 800.00%. Aclarion has a consensus price target of $11,758.50, suggesting a potential upside of 158,584.21%. Given Aclarion's higher possible upside, analysts plainly believe Aclarion is more favorable than BioRestorative Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioRestorative Therapies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aclarion 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in BRTX or ACON? Aclarion received 2 more outperform votes than BioRestorative Therapies when rated by MarketBeat users. However, 100.00% of users gave BioRestorative Therapies an outperform vote while only 57.14% of users gave Aclarion an outperform vote. CompanyUnderperformOutperformBioRestorative TherapiesOutperform Votes2100.00% Underperform VotesNo VotesAclarionOutperform Votes457.14% Underperform Votes342.86% Do insiders & institutionals have more ownership in BRTX or ACON? 69.4% of BioRestorative Therapies shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 25.5% of BioRestorative Therapies shares are held by insiders. Comparatively, 0.8% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is BRTX or ACON more profitable? BioRestorative Therapies has a net margin of -2,697.08% compared to Aclarion's net margin of -12,845.05%. BioRestorative Therapies' return on equity of -98.49% beat Aclarion's return on equity.Company Net Margins Return on Equity Return on Assets BioRestorative Therapies-2,697.08% -98.49% -75.23% Aclarion -12,845.05%-422.87%-201.15% Does the media prefer BRTX or ACON? In the previous week, BioRestorative Therapies had 2 more articles in the media than Aclarion. MarketBeat recorded 4 mentions for BioRestorative Therapies and 2 mentions for Aclarion. Aclarion's average media sentiment score of 1.43 beat BioRestorative Therapies' score of 0.86 indicating that Aclarion is being referred to more favorably in the news media. Company Overall Sentiment BioRestorative Therapies Positive Aclarion Positive SummaryBioRestorative Therapies beats Aclarion on 11 of the 16 factors compared between the two stocks. Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACON vs. The Competition Export to ExcelMetricAclarionMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.31M$3.10B$5.61B$8.62BDividend YieldN/A31.25%5.28%4.17%P/E RatioN/A14.2127.1419.96Price / Sales78.98178.39411.84157.63Price / CashN/A57.5638.2534.64Price / Book-0.064.757.064.69Net Income-$4.91M-$22.21M$3.23B$248.14M7 Day Performance7.86%3.83%0.80%0.95%1 Month Performance1.23%6.85%9.71%5.74%1 Year Performance-99.72%15.47%32.12%14.73% Aclarion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACONAclarion2.5007 of 5 stars$7.41-3.6%$11,758.50+158,584.2%-99.7%$4.31M$54.60K0.007Short Interest ↓BRTXBioRestorative Therapies3.9372 of 5 stars$1.81+0.3%$18.00+894.5%+48.1%$13.58M$391K-1.187High Trading VolumeMGRXMangoceuticals0.5312 of 5 stars$2.05+0.5%N/A-97.6%$10.60M$511.08K-0.353Short Interest ↑SSYSunLink Health Systems1.0914 of 5 stars$1.00+13.0%N/A+34.7%$7.01M$31.09M7.111,376Short Interest ↑OTRKOntrak2.6088 of 5 stars$1.47-3.9%$45.00+2,961.2%-57.9%$6.20M$10.18M-0.14250BGLCBioNexus Gene Lab0.2176 of 5 stars$3.07-1.0%N/A-38.7%$5.52M$9.27M0.0030Gap UpVSEEVsee Health2.3922 of 5 stars$1.14+0.1%$5.00+338.2%N/A$4.11M$6.38M0.00N/AGap UpDHACDigital Health AcquisitionN/A$1.14+0.9%N/A-92.3%$4.11MN/A0.002,021ATIPATI Physical Therapy0.3035 of 5 stars$0.93-7.3%N/A-77.0%$4.09M$741.86M-0.055,600NIVFNewGenIvf Group2.1918 of 5 stars$1.91-13.2%N/A-99.2%$1.01M$5.43M0.00N/ANews CoverageBACKIMACN/A$0.04+8.5%N/A-98.6%$92K$72.05K0.00180Gap Up Related Companies and Tools Related Companies BioRestorative Therapies Competitors Mangoceuticals Competitors SunLink Health Systems Competitors Ontrak Competitors BioNexus Gene Lab Competitors Vsee Health Competitors Digital Health Acquisition Competitors ATI Physical Therapy Competitors NewGenIvf Group Competitors IMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACON) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
